National Cancer Institute  www.cancer.gov  U.S. National Institutes of Health
 


Cancer Trends Progress Report – 2011/2012 Update

Skip to content
Progress Report  Home

Progress Report Tools
 Print this page
 Generate custom report



In the Report
Introduction
Trends-at-a-Glance
Summary Tables
Prevention
Early Detection
Diagnosis
Treatment
Bladder Cancer Treatment
> Breast Cancer Treatment
Colorectal Cancer Treatment
Kidney Cancer Treatment
Lung Cancer Treatment
Ovarian Cancer Treatment
Prostate Cancer Treatment
Life After Cancer
End of Life



Breast Cancer Treatment
Treatment

The proportion of women with node positive disease receiving appropriate treatment is high. Older women are less likely to receive chemotherapy than younger women, but there are no major differences in treatment among major racial and ethnic groups.

On this page:

Breast-conserving Surgery and Radiation Treatment
Benefits of Treatment

Clinical trials have demonstrated that women with early-stage breast cancer who receive breast-conserving surgery with radiation have survival similar to women who receive a mastectomy. A 1990 NIH Consensus Development Panel concluded that "breast conservation treatment (BCS followed by radiation therapy) is an appropriate method of primary therapy for the majority of women with stage I and II breast cancer and is preferable because it provides survival equivalent to total mastectomy and axillary dissection while preserving the breast."

Back to Top

Measure

Percentage of women age 20 and older, diagnosed with early-stage breast cancer (less than stage IIIA), receiving breast-conserving surgery and radiation treatment.

Back to Top

Period – 1992–2008

Back to Top

Trends – Rising between 1992 and 1998, falling between 2004 and 2008.

Back to Top

Most Recent Estimates

In 2008, 37 percent of women age 20 and older diagnosed with early-stage breast cancer (less than stage IIIA) received a mastectomy, 41 percent received breast-conserving surgery plus radiation, and 19 percent received breast-conserving surgery only.

Back to Top

Healthy People 2020 Targets

There are no Healthy People targets for cancer treatment, including breast cancer treatment.

Back to Top

Multi-agent Chemotherapy
Benefits of Treatment

For women with positive lymph nodes, multi-agent chemotherapy has been recommended by NIH since 1985. However, the NIH Consensus Conference on Breast Cancer in 2000 stated insufficient numbers of women age 70 or older were included in clinical trials to make a recommendation about chemotherapy. Based on the results of numerous randomized, controlled treatment trials, tamoxifen has been recommended for women with estrogen-receptor positive breast cancer.

Back to Top

Measure

Percentage of women age 20 and older, diagnosed with node positive, stage I–IIIa breast cancer, receiving multi-agent chemotherapy.

Back to Top

Period – 1987–2005

Back to Top

Trends – Rising use through 1995 but stable after that time.

Back to Top

Most Recent Estimates

In 2005, 67 percent of women age 20 and older diagnosed with node positive breast cancer received multi-agent chemotherapy. A breast cancer NCI patterns of care study is currently being conducted for diagnosis year 2010.

Back to Top

Healthy People 2020 Targets

There are no Healthy People targets for cancer treatment, including breast cancer treatment, and multi-agent chemotherapy.

Back to Top

Groups at High Risk for Not Receiving Appropriate Treatment

Studies have found that older women are less likely to receive radiation treatment following breast-conserving surgery. Even elderly patients with no or very few co-morbid conditions—such as diabetes, kidney, or heart disease—were less likely to receive treatment. Although there are no clear guidelines for the use of chemotherapy in women age 70 or older, the use of chemotherapy is lower among older women.

Back to Top

Key Issues

Emerging treatments for breast cancer include the anti-HER2/neu antibody, trastuzumab for patients with HER2 over expressing cancers, and aromatase inhibitors either in conjunction with or instead of tamoxifen. The inclusion of women age 70 or older in clinical trials is necessary to determine the benefit of more aggressive therapies.

Back to Top

Additional Information on Breast Cancer Treatment

Back to Top

Back: Bladder Cancer Treatment

National Cancer InstituteDepartment of Health and Human ServicesNational Institutes of HealthUSA.gov

NIH... Turning Discovery Into Health